FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C δ Signaling
Open Access
- 15 February 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (4) , 1204-1212
Abstract
This study was aimed at elucidating the mechanism by which FTY720, a synthetic sphingosine immunosuppressant, mediated antitumor effects in hepatocellular carcinoma (HCC) cells. The three HCC cell lines examined, Hep3B, Huh7, and PLC5, exhibited differential susceptibility to FTY720-mediated suppression of cell viability, with IC50 values of 4.5, 6.3, and 11 μmol/L, respectively. Although FTY720 altered the phosphorylation state of protein kinase B and p38, our data refuted the role of these two signaling kinases in FTY720-mediated apoptosis. Evidence indicates that the antitumor effect of FTY720 was attributable to its ability to stimulate reactive oxygen species (ROS) production, which culminated in protein kinase C (PKC)δ activation and subsequent caspase-3–dependent apoptosis. We showed that FTY720 activated PKCδ through two distinct mechanisms: phosphorylation and caspase-3–dependent cleavage. Cotreatment with the caspase-3 inhibitor Z-VAD-FMK abrogated the effect of FTY720 on facilitating PKCδ proteolysis. Equally important, pharmacologic inhibition or shRNA-mediated knockdown of PKCδ protected FTY720-treated Huh7 cells from caspase-3 activation. Moreover, FTY720 induced ROS production to different extents among the three cell lines, in the order of Hep3B > Huh7 >> PLC5, which inversely correlated with the respective glutathione S-transferase π expression levels. The low level of ROS generation might underlie the resistant phenotype of PLC5 cells to the apoptotic effects of FTY720. Blockade of ROS production by an NADPH oxidase inhibitor protected Huh7 cells from FTY720-induced PKCδ activation and caspase-3–dependent apoptosis. Together, this study provides a rationale to use FTY720 as a scaffold to develop potent PKCδ-activating agents for HCC therapy. [Cancer Res 2008;68(4):1204–12]Keywords
This publication has 45 references indexed in Scilit:
- FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphomaBlood, 2008
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemiaJournal of Clinical Investigation, 2007
- Hepatocellular Carcinoma (HCC): An UpdateSeminars in Oncology, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsJournal of Biological Chemistry, 2002
- Infection of Glioma Cells with Sindbis Virus Induces Selective Activation and Tyrosine Phosphorylation of Protein Kinase C δJournal of Biological Chemistry, 2002
- Caspase activation and disruption of mitochondrial membrane potential during UV radiation-induced apoptosis of human keratinocytes requires activation of protein kinase CCell Death & Differentiation, 2002
- Subtype-Specific Translocation of the δ Subtype of Protein Kinase C and Its Activation by Tyrosine Phosphorylation Induced by Ceramide in HeLa CellsMolecular and Cellular Biology, 2001